Status:

RECRUITING

A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab

Lead Sponsor:

AbbVie

Conditions:

Hidradenitis Suppurativa

Atopic Dermatitis

Eligibility:

All Genders

18-75 years

Phase:

PHASE2

Brief Summary

Hidradenitis suppurativa (HS) and atopic dermatitis (AD) are chronic inflammatory skin diseases that lead to the development of skin lesions and symptoms such as pain and discomfort. The purpose of th...

Eligibility Criteria

Inclusion

  • Sub-Study 1 hidradenitis suppurativa (HS):
  • Participants with a diagnosis of moderate-to-severe HS for at least 6 months prior to Baseline as determined by the investigator
  • Participants naïve to biologic treatment for HS or must have a prior inadequate response or loss of response to anti-TNF therapy for HS (\>= 12 weeks of therapy).
  • Sub-Study 2 atopic dermatitis (AD):
  • Participants with a diagnosis of moderate-to-severe AD with onset of symptoms at least 1 year prior to Baseline.
  • Participants naïve to biologic treatment for AD or must have a prior inadequate response or loss of response to dupilumab for AD (defined as \>= 8 weeks of therapy with dupilumab).

Exclusion

  • History of any malignancy within the last 5 years except for successfully treated nonmelanoma skin cancer (NMSC) or localized carcinoma in situ of the cervix.
  • History of active skin disease (other than HS for Sub-Study 1 or AD for Sub-Study 2) that could interfere with the assessment of HS (for Sub-Study 1) or AD (for Sub-Study 2), including skin infections (e.g., bacterial, fungal, or viral) requiring systemic treatment within 4 weeks of the Baseline.

Key Trial Info

Start Date :

August 14 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

February 1 2027

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT06524635

Start Date

August 14 2024

End Date

February 1 2027

Last Update

January 24 2025

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Physioseq, LLC /ID# 267266

Sacramento, California, United States, 95825

2

University of Michigan Health System - Ann Arbor /ID# 267275

Ann Arbor, Michigan, United States, 48109

A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab | DecenTrialz